Eli Lilly and Company (LLY) Projected to Post Quarterly Earnings on Thursday

Eli Lilly and Company (NYSE:LLY - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $5.45 per share and revenue of $13.69 billion for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The business's quarterly revenue was up 20.4% compared to the same quarter last year. On average, analysts expect Eli Lilly and Company to post $13 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $19.51 during mid-day trading on Thursday, hitting $823.59. The stock had a trading volume of 2,641,960 shares, compared to its average volume of 3,922,886. Eli Lilly and Company has a fifty-two week low of $637.00 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company's 50-day simple moving average is $780.80 and its 200-day simple moving average is $845.98. The firm has a market cap of $781.85 billion, a PE ratio of 89.04, a PEG ratio of 1.59 and a beta of 0.41.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Redburn Atlantic upgraded Eli Lilly and Company to a "hold" rating in a research note on Monday, November 4th. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price target on the stock. Wells Fargo & Company reduced their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating for the company in a research note on Tuesday. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a report on Thursday, October 10th. Finally, StockNews.com downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $997.22.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.